Pamrevlumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Pamrevlumab
Accession Number
DB14952
Type
Biotech
Groups
Investigational
Description

Pamrevlumab is under investigation in clinical trial NCT00913393 (Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy).

Synonyms
Not Available
External IDs
FG-3019
Categories
UNII
QS5F6VTS0O
CAS number
946415-13-0

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Pamrevlumab.
AbituzumabThe risk or severity of adverse effects can be increased when Abituzumab is combined with Pamrevlumab.
AbrilumabThe risk or severity of adverse effects can be increased when Pamrevlumab is combined with Abrilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Pamrevlumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Pamrevlumab.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Pamrevlumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Pamrevlumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Pamrevlumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Pamrevlumab.
AmatuximabThe risk or severity of adverse effects can be increased when Amatuximab is combined with Pamrevlumab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Pamrevlumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentDiabetes Mellitus1
1CompletedTreatmentDiabetes Mellitus / Diabetic Nephropathies1
1CompletedTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
1CompletedTreatmentLocally Advanced or Metastatic Pancreatic Cancer1
1TerminatedTreatmentGlomerulosclerosis, Focal Segmental1
1, 2Active Not RecruitingTreatmentPancreatic Cancer (Unresectable)1
2Active Not RecruitingTreatmentDuchenne's Muscular Dystrophy (DMD)1
2CompletedTreatmentIdiopathic Pulmonary Fibrosis (IPF)2
2RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19)1
2TerminatedTreatmentDiabetic Kidney Disease / Diabetic Nephropathies / Type 2 Diabetes Mellitus1
2TerminatedTreatmentLiver Fibrosis Due to Chronic Hepatitis B Infection1
3Not Yet RecruitingTreatmentDuchenne's Muscular Dystrophy (DMD)1
3Not Yet RecruitingTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
3RecruitingTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
3RecruitingTreatmentPancreatic Cancer Non-resectable1
Not AvailableWithdrawnTreatmentMalignant Neoplasm of Pancreas1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:37 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates